June 2, 2021 -- Danaher has acquired Precision NanoSystems, a Canadian developer of genetic medicines including messenger RNA (mRNA) vaccines.
Precision NanoSystems provides technology that supports the development and manufacturing of lipid nanoparticles to help deliver genetic medicines, including mRNA vaccines. The companies cited the rapid growth of the mRNA segment as one of the reasons behind the deal.
Precision NanoSystems will join Danaher's life sciences platform and will complement other Danaher subsidiaries including Cytiva and Pall. Precision NanoSystems will continue to develop a new manufacturing center in Vancouver as planned.